GlobeNewswire Inc | Dec 10, 2020 11:15AM EST

December 10, 2020

LOS ANGELES, Dec. 10, 2020 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion.

Investors suffering losses on their investments are encouraged to contact The Law Offices of Frank R. Cruz to discuss their legal rights in these class actions at 310-914-5007 or by email to fcruz@frankcruzlaw.com.

HP Inc. (NYSE: HPQ)Class Period: November 6, 2015 June 21, 2016Lead Plaintiff Deadline: January 4, 2021

The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Companys business, operations, and prospects. Specifically, Defendants failed to disclose: (1) that HPs channel inventory management and sales practices resulted in the sale of supplies to customers that did not need or want the product in order to artificially increase revenues and profits; (2) that HPs channel inventory management and sales practices resulted in the sale of supplies to customers outside of designated regions at unsustainable discounts in order to artificially increase revenues and profits; (3) that HPs channel inventory management and sales practices resulted in the sale of supplies at steep discounts to customers to encourage those customers to sell the supplies further down the supply channel, out of HPs inventory management metrics; and (4) that, as a result of the foregoing, defendants statements about the Companys business condition and prospects were materially false and misleading when made.

Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT)Class Period: September 28, 2019 October 7, 2020Lead Plaintiff Deadline: January 4, 2021

The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Companys business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) Defendants downplayed the true scope and severity of safety concerns associated with Ocalivas use in treating PBC; (2) the foregoing increased the likelihood of an FDA investigation into Ocalivas development, thereby jeopardizing Ocalivas continued marketability and the sustainability of its sales; (3) any purported benefits associated with OCAs efficacy in treating NASH were outweighed by the risks of its use; (4) as a result, the FDA was unlikely to approve the Companys NDA for OCA in treating patients with liver fibrosis due to NASH; and (5) as a result of all the foregoing, the Companys public statements were materially false and misleading at all relevant times.

Neovasc Inc. (NASDAQ: NVCN)Class Period: October 10, 2018 October 27, 2020Lead Plaintiff Deadline: January 5, 2021

Shareholders with $500,000 losses or more are encouraged to contact the firm

The complaint filed alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Companys business, operations, and prospects. Specifically, Defendants failed to disclose to investors: (1) that the results of COSIRA, Neovascs clinical study for the Reducer, contained imbalances in missing information present in the control group versus the treatment group, including significant missing information for secondary endpoints but none for the primary endpoint; (2) that the imbalance in missing information indicated that control subjects were aware of their treatment assignment (not blinded) and less inclined to participate in additional data collection; (3) that blinding is critical when studying a placebo-responsive condition such as angina; (4) that the lack of blinding assessment made the primary endpoint difficult to interpret; (5) that, as a result of the foregoing, the FDA was reasonably likely to require additional premarket clinical data; (6) that, as a result, the Companys PMA for Reducer was unlikely to be approved without additional clinical data; and (7) that, as a result of the foregoing, Defendants positive statements about the Companys business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Follow us for updates on Twitter: twitter.com/FRC_LAW.

To be a member of these class actions, you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action. If you wish tolearn moreabout these class actions, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Frank R. Cruz, of The Law Offices of Frank R. Cruz, 1999 Avenue of the Stars, Suite 1100, Los Angeles, California 90067 at 310-914-5007, by email to info@frankcruzlaw.com, or visit our website at www.frankcruzlaw.com. If you inquire by email please include your mailing address, telephone number, and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contacts

The Law Offices of Frank R. Cruz, Los AngelesFrank R. Cruz, 310-914-5007fcruz@frankcruzlaw.comwww.frankcruzlaw.com